Eflornithine oral - Panbela Therapeutics
Alternative Names: CPP-1X; CPP-1X-S; CPP-1X-T; D,L-ɑdifluoromethylornithine; DFMO; Difluoromethylornithine; Difluoromethylornithine (DFMO); IFINWIL; IWILFINLatest Information Update: 24 Apr 2025
At a glance
- Originator Cancer Prevention Pharmaceuticals
- Developer Atrium Health; Children's Oncology Group; Indiana University; KC Pharmaceuticals; National Cancer Institute (USA); New Approaches to Neuroblastoma Therapy Consortium; Norgine; Panbela Therapeutics; US WorldMeds; Vanderbilt University Medical Center
- Class Antihyperglycaemics; Antineoplastics; Basic amino acids; Diamino amino acids; Small molecules
- Mechanism of Action Ornithine decarboxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neuroblastoma
- Phase II Colorectal cancer; Gastric cancer; Prostate cancer; Type 1 diabetes mellitus
- Phase I/II Non-small cell lung cancer
- Preclinical Cancer; Multiple myeloma
Most Recent Events
- 17 Apr 2025 Registered for Neuroblastoma (In adolescents, In children, Second-line therapy or greater, In adults) in Australia (PO)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In adolescents, In adults) in USA (PO, Powder)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Neuroblastoma in USA (PO, Tablet)